UPDATE ON PFIZER’S PHASE 1B OPEN-LABEL MINI-DYSTROPHIN GENE THERAPY TRIAL FOR DUCHENNE, page-16

Anp has to be very careful with its money. We have enough cash to get us to futility with the DMD trial. And thats where the BOD need to be concentrating. As Sam and others have said before, good results at futility means the drug is working, hence the trial has been derisked at that point, and the market cap should hopefully reflect that.

DMD approval, and commercialisation will generate revenues that can be used to pursue other indications without further dilution and providing greater shareholder return.

Data from this DMD trial will help progress ATL1102 into other indications. Add the FDA tox trial and safety will become a well known factor. So time frames for other indications will be reduced.

ANP has a potentially large and diverse pipeline from just the one drug. As has been stated above, the way in which ATL1102 treats DMD, and MS, makes these really other subsets of the greater inflammation indication when a big picture viewpoint is taken. Data from this trial will help ATL1102 in other CD49 indications as greater data points are achieved. Refer to itsas valuations of the inflammation market. And new research is showing that the inflammation area is growing into other indications, cancer for example.

So. in my opion, full attention on DMD now through to commercialisation and then spinning off to other indications would give the shareholder best bang for the buck over the longer term. We are still a $100 million drug discovery biotech. We are approaching an important pivot point, which if successful will be a major company maker and still have lots of future growth potential, all from the one drug